Anzeige
Mehr »
Login
Montag, 23.05.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Weltweit erstes Patent zur Muskel-Gesundheit macht Furore! Durch klinische Studien belegt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKZC ISIN: US0887861088 Ticker-Symbol: 50BA 
Tradegate
19.05.22
15:47 Uhr
16,300 Euro
-0,100
-0,61 %
1-Jahres-Chart
BICYCLE THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BICYCLE THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
16,20016,50022.05.
16,30016,40020.05.

Aktuelle News zur BICYCLE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.05.Expert Ratings for Bicycle Therapeutics-
BICYCLE THERAPEUTICS Aktie jetzt für 0€ handeln
05.05.Bicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55M-
05.05.BICYCLE THERAPEUTICS plc - 10-Q, Quaterly Report-
05.05.BICYCLE THERAPEUTICS plc - 8-K, Current Report1
05.05.Bicycle Therapeutics plc: Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update147Continued clinical progress across pipeline, including interim BT8009 Phase I clinical data Cash and cash equivalents of $407.4 million as of March 31, 2022 expected to provide financial runway through...
► Artikel lesen
14.04.Hot Stocks: Travel stocks rally; SRRA, ATRS jump on merger deals; NSTG plunges; BCYC extends low4
13.04.B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $331
13.04.Where Bicycle Therapeutics Stands With Analysts1
13.04.B. Riley downgrades Bicycle Therapeutics on uncertain path for BT8009-
12.04.BICYCLE THERAPEUTICS plc - 8-K, Current Report-
12.04.Bicycle Therapeutics plummets as price target cut to $75 by Needham1
12.04.Bicycle Therapeutics reports promising BT8009 study results, shares tank 30%-
11.04.Here's Why Bicycle Therapeutics Stock Looks Ill Today7
11.04.Bicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer data1
11.04.Bicycle Therapeutics plc: Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting15850% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m2 weekly Median duration of response not yet reached in...
► Artikel lesen
08.04.Why Bicycle Therapeutics Stock Is Soaring Today4
08.04.Bicycle Therapeutics gains on early-stage data for oncology asset in bladder cancer2
08.04.Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting269Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics...
► Artikel lesen
07.04.Bicycle Therapeutics plc: Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting206Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced...
► Artikel lesen
08.03.Bicycle Therapeutics plc: Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference146Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced...
► Artikel lesen
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1